Cargando…
TAF1 inhibitor Bay-299 induces cell death in acute myeloid leukemia
BACKGROUND: Acute myeloid leukemia (AML) is one of the most common hematopoietic malignancies. The cure rate of currently intensive chemotherapy in AML was only 40% or less, and there is an urgent need to develop novel effective therapeutic targets or drugs. The TATA-box binding protein associated f...
Autores principales: | Zhou, Lixin, Yao, Qi, Ma, Le, Li, Hui, Chen, Jieping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798726/ https://www.ncbi.nlm.nih.gov/pubmed/35116379 http://dx.doi.org/10.21037/tcr-21-2295 |
Ejemplares similares
-
Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells
por: Zhou, Lixin, et al.
Publicado: (2021) -
Taf2 mediates DNA binding of Taf14
por: Klein, Brianna J., et al.
Publicado: (2022) -
Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
por: Chaturvedi, Anuhar, et al.
Publicado: (2020) -
Benzoisoquinolinediones
as Potent and Selective Inhibitors
of BRPF2 and TAF1/TAF1L Bromodomains
por: Bouché, Léa, et al.
Publicado: (2017) -
SUMOylation of sPRDM16 promotes the progression of acute myeloid leukemia
por: Dong, Song, et al.
Publicado: (2015)